辉瑞百亿BD创纪录,却多出两个“受害者”

健识局
20 May

康方生物 栽的树,让 三生制药 乘了凉。5月20日,三生制药将PD-1/VEGF双抗SSGJ-707的海外权益卖给了辉瑞,交易总金额高达60.5亿美元。其中,仅首付款就高达12.5亿美元,约合人民币90亿元,已经抵得上三生制药2024一整年的收入。此外,辉瑞豪掷1亿美元入股三生制药,对于三生制药SSGJ-707的期待已经明牌。对康方生物来说这可能算不上一个好消息。今年2月,辉瑞才刚刚跟康方生物的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10